Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for ImExHS's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IME vs TMO, DHR, IDXX: Total Payout Ratio Comparison
For the Diagnostics & Research subindustry, ImExHS's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImExHS Total Payout Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ImExHS's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where ImExHS's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImExHS (ASX:IME) has a Total Payout Ratio of 0.83 as of Jul. 14, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on ImExHS and its competitors.
Is ImExHS's Total Payout Ratio too high?
ImExHS's current Total Payout Ratio is 0.83. Overall, ImExHS has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ImExHS's Total Payout Ratio compare to TMO and DHR?
ImExHS's Total Payout Ratio of 0.83 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Medical Diagnostics & Research company?
A good Total Payout Ratio depends on the Medical Diagnostics & Research industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on ImExHS and its competitors. ImExHS's current Total Payout Ratio is 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImExHS stock overvalued right now?
Based on GuruFocus' analysis, ImExHS (ASX:IME) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.31 — trading 39.2% below its estimated fair value. The current Total Payout Ratio is 0.83. ImExHS's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For ImExHS (ASX:IME), the current Total Payout Ratio is 0.83 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImExHS (ASX:IME) Overvalued in 2026?
Based on GuruFocus' analysis, ImExHS stock appears to be undervalued.
The current stock price of A$0.31 is trading 39.2% below its estimated GF Value™ of A$0.51.
GuruFocus considers ImExHS to be Possible Value Trap.
Key valuation signals for ASX:IME:
Total Payout Ratio: 0.83
GF Value™: A$0.51 vs. price of A$0.31 (39.2% below fair value)
No single metric tells the full story. See the ASX:IME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImExHS Ltd is a healthcare technology company engaged in the provision of medical imaging software and radiology services. The company develops and delivers enterprise imaging solutions, including radiology information systems and picture archiving and communication systems, as well as provides diagnostic imaging and teleradiology services to healthcare institutions. The company operates through two reportable segments: Software, which focuses on the development and sale of imaging systems and platforms, and Radiology Services, which provides diagnostic and teleradiology services to hospitals and medical facilities. It generates the majority of its revenue from the Radiology segment.
52GF Score
Get the complete analysis for ASX:IME
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IME has been successfully added to your 
